innovative platform technology

Innovative Technology Platform

Entera's innovative technology enables oral drug delivery of large molecules

27163516 pills

Pipeline of Drug Development

Entera conducts clinical trials of three oral drugs based on a proven active compound

27163516 brain green

Experienced Management Team

The managers of Entera have more than 50 years of experience in drug development

December 22, 2015 – Mr. Luke M. Beshar, the former Executive Vice President and Chief Financial Officer (CFO) of NPS Pharmaceuticals, Inc. was appointed to Entera’s board of directors. Mr. Beshar brings more than 35 years of leadership experience to Entera's board. Mr. Beshar helped reposition NPS as a leading global rare disease biopharmaceutical company, and was a key member of the team that led the $5.2 billion sale of NPS to Shire plc in February 2015.